Moderna Launches Flu Vaccine Trial, Targets Single Jab For Multiple Diseases
18:35 GMT 07.07.2021 (Updated: 08:56 GMT 15.11.2022)
© AFP 2023 / JOSEPH PREZIOSOIn this file photo the Moderna logo is seen at the Moderna campus in Norwood, Massachusetts on on December 2, 2020, where the biotechnology company is mass producing its Covid-19 vaccine. - US biotech firm Moderna said on July 7, 2021 it had dosed its first participants in a human study of an mRNA vaccine that targets multiple strains of influenza. The company intends to recruit 180 adults in the United States for the Phase 1/2 portion of the trial to evaluate the safety and strength of immune response to the shot, called mRNA-1010.
© AFP 2023 / JOSEPH PREZIOSO
WASHINGTON (Sputnik) - The onset of a flu vaccine trial using messenger-RNA (mRNA) technology could lead to a single jab targeting multiple respiratory diseases, including COVID-19, vaccine maker Moderna said on Wednesday.
Moderna’s goal of making a single vaccine against multiple viruses was included in a press release announcing the onset of a phase 1 study of mRNA-1010, the company’s seasonal influenza vaccine candidate. The company said it plans to enroll 180 participants in the trial.
"Respiratory combination vaccines are an important pillar of our overall mRNA vaccine strategy", the release said. "We believe that the advantages of mRNA vaccines include the ability to combine different antigens to protect against multiple viruses".
Conventional vaccines use all or part of a modified pathogen to trigger an immune response. In contrast, the mRNA - used in both Moderna and Pfizer COVID-19 jabs - instructs cells to produce copies of the spike protein on the coronavirus surface. The protein then causes the body to develop immunity.
Messenger RNA vaccines offer a number of advantages over traditional inoculations in that they can be quickly designed and scaled up, using a manufacturing process that is highly adaptable to different pathogens, according to the National Institutes of Health.